

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


On April 29, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
Attorney Docket No.: 021044-005510US
Client Reference No.:
P.0020.01.US.UT.NPC.RR



In re application of:

Luo et al.

Application No.: 09/762,491

Filed: May 9, 2001

For: NOVEL APOPTOSIS PROTEINS

Examiner: Misook YU

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are not enclosed as they were submitted to the U.S. PTO on August 1, 2003, and have been placed in the application file as advised by the Examiner. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


Also in the application file is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:jhd
60205959 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 3

Complete if Known

Application Number	09/762,491
Filing Date	May 9, 2001
First Named Inventor	Luo, Ying
Art Unit	1642
Examiner Name	Misook YU
Attorney Docket Number	021044-005510US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AA	WO	97/15586	A1	05-01-1997	Baichwal, V., et al.		<input type="checkbox"/>
	AB	WO	96/36730	A1	11-21-1996	Leder, P., et al.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	CAO, et al., "Human Gastric Adenocarcinoma Cathepsin B: Isolation and Sequencing of Full-Length cDNAs and Polymorphisms of the Gene", <i>Gene</i> (1994), Vol. 139, pp. 163-169	
	AD	CHAN, et al., "Nucleotide and Predicted Amino Acid Sequences of Cloned Human and Mouse Preprocathepsin B cDNAs", <i>Proceedings of the National Academy of Sciences USA</i> (1986), Vol. 83, pp. 7721-7725	
	AE	COHEN, Gerald, M., "Caspases: the Executioners of Apoptosis", <i>Biochemistry Journal</i> (1997), Vol. 326, pp. 1-16	
	AF	DEL PESO, L., et al., "Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt", <i>Science</i> (1997), Vol. 278, pp. 687-689	
	AG	FONG, D., et al., "Isolation of a cDNA Clone for the Human Lysosomal Proteinase Cathepsin B, <i>Proceedings of the National Academy of Sciences USA</i> (1986), Vol. 83, pp. 2909-2913	
	AH	MOIN, K., et al., "Human Tumour Cathepsin B - Comparison with Normal Liver Cathepsin B", <i>Biochemical Journal</i> (1992), Vol. 285, pp. 427-434	
	AI	NÄGLER, D. et al., "Full-Length cDNA of Human Cathepsin F Predicts the Presence of a Cystatin Domain at the N-terminus of the Cysteine Protease Zymogen", <i>Biochemical and Biophysical Research Communications</i> (1999) Vol. 257, pp. 313-318	
	AJ	RITONJA, A., et al., "Amino Acid Sequence of Human Liver Cathepsin B", <i>Federation of European Biochemical Societies</i> , (1985), Vol. 181, No. 1, pp. 169-172	
	AK	SANTAMARIA, I., et al., "Molecular Cloning and Structural and Functional Characterization of Human Cathepsin F, a New Cysteine Proteinase of the Papain Family with a Long Propeptide Domain", <i>Journal of Biological Chemistry</i> (1999), Vol. 274, No. 20, pp. 13800-13809	
	AL	SUN, X., et al., <i>The Journal of Biological Chemistry</i> (1999), Vol. 274, No. 24, pp. 16871-16875	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 2 of 3

Complete if Known

Application Number	09/762,491
Filing Date	May 9, 2001
First Named Inventor	Luo, Ying
Art Unit	1642
Examiner Name	Misook YU
Attorney Docket Number	021044-005510US

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	TAKAHASHI, R., et al., "A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases, <i>The Journal of Biological Chemistry</i> (1998), Vol. 273, No. 14, pp. 7787-7790	
	AN	THOME, M., et al., "Syk and ZAP-70 Mediate Recruitment of p56 ^{lck} /CD4 to the Activated T Cell Receptor/CD3/ ζ Complex", <i>Journal of Experimental Medicine</i> (1995), Vol. 181, pp. 1997-2006	
	AO	WANG, B., et al., "Human Cathepsin F - Molecular Cloning, Functional Expression, Tissue Localization, and Enzymatic Characterization", <i>Journal of Biological Chemistry</i> (1998), Vol. 273, No. 48, pp. 32000-32008	
	AP	WEX, TH., et al. "Human Cathepsins F and W: A New Subgroup of Cathepsins", <i>Biochemical and Biophysical Research Communications</i> (1999), Vol. 259, pp. 401-407	
	AQ	YU, P., et al., "Identification of RIP3, a RIP-like Kinase That Activates Apoptosis and NF κ B", <i>Current Biology</i> (1999), Vol. 9, pp. 539-542	
	AR	Accession No. NM_001908, submitted August 29, 2002	
	AS	Accession No. M14221, submitted 1986	
	AT	Accession No. P07858, submitted July 1, 1989	
	AU	Accession No. NP_001899, submitted 1986	
	AV	Accession No. AF071748, submitted June 9, 1998	
	AW	Accession No. NM_003793, submitted October 15, 1999	
	AX	Accession No. AF088886, submitted May 3, 1999	
	AY	Accession No. AJ007331, submitted June 20, 1998	
	AZ	Accession No. AF132894, submitted March 3, 1999	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/762,491		
		Filing Date	May 9, 2001		
		First Named Inventor	Luo, Ying		
		Art Unit	1642		
		Examiner Name	Misook YU		
Page	3	of	3	Attorney Docket Number	021044-005510US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	Accession No. AA338898, submitted April 21, 1997	
	BB	Accession No. H39591, submitted July 31, 1995	
	BC	Accession No. AA378321, submitted April 21, 1997	
	BD	Accession No. AA227673, submitted November 27, 1996	
	BE	Accession No. N99896, submitted April 15, 1996	
	BF	Accession No. AI394293, submitted February 4, 1999	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.